Skip to main content

Table 1 Baseline characteristics

From: Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Median age, years (range) 73 (33–91)
WHO diagnosis*, n (%)  
 t-AML 16 (10.3)
 AML-RCA 16 (10.3)
 AML-MRF only 88 (56.8)
   AML-MRC 13 (8.4)
   Preexisting MDS/MPN or MLD 58 (37.4)
   Preexisting MDS/MPN or MLD + MRC 17 (11.0)
   AML-NOS 35 (22.6)
Peripheral blood blasts, n (%)  
 0% 58 (37.4)
 > 0% 97 (62.6)
 Mean,% 14
 Median (range),% 3 (0–90)
Bone marrow blasts, n (%)  
 <20%† 26 (16.8)
 20–30% 31 (20.0)
 >30% (off label use) 98 (63.2)
 Mean,% 42
 Median (range),% 35 (0–98)
White blood cell count, n (%)  
 Non-MP-AML (< 10 G/l) 122 (78.7)
 MP-AML (> 10 G/l) 33 (21.3)
Transfusion dependence (TD), n (%)  
 Any type of TD 101 (65.2)
 RBC-TD 97 (62.6)
 PLT-TD 60 (38.7)
 RBC-TD + PLT-TD 56 (36.1)
IPSS cytogenetic risk, n (%)  
 Not evaluable 11 (7.1)
 Good 91 (58.7)
 Intermediate 26 (16.1)
 Poor 27 (17.4)
MRC cytogenetic risk, n (%)  
 Not evaluable 11 (7.1)
 Good 3 (1.9)
 Intermediate 115 (74.2)
 High 26 (16.8)
Comorbidities, n (%)  
 Thromboembolic episodes 21 (13.5)
 Renal insufficiency 29 (18.7)
 Liver disease 20 (12.9)
 Diabetes mellitus 26 (16.8)
 Coronary artery disease 34 (21.9)
 COPD 15 (9.7)
 Prior/concomitant malignancies 35 (22.6)
Number of comorbidities, n (%)  
 0–1 66 (42.6)
 2–3 61 (39.4)
 > 3 28 (18.1)
ECOG Prognostic Score, n (%)  
 ECOG <2 114 (73.6)
 ECOG ≥2 41 (26.4)
HCT-CI, n (%)  
 Low risk 46 (29.7)
 Int. risk 46 (29.7)
 High risk 50 (32.2)
 No data 13 (8.4)
Treatment prior to azacitidine§, n (%)  
 None 63 (40.6)
 Erythropoietin stimulating agents 15 (9.7)
 G-CSF 19 (12.3)
 Thrombopoietin stimulating agents 1 (0.7)
 Iron chelation therapy 5 (3.2)
 Thalidomide 3 (1.9)
 Lenalidomide 6 (3.9)
 Low-dose cytarabine 10 (6.5)
 Intensive chemotherapy 60 (38.7)
 Others 16 (10.3)
Reason for treatment, n (%)  
 1st line treatment 63 (40.6)
 Bridging to allogeneic SCT# 4 (2.6)
 Maintenance after CR to conventional chemotherapy 6 (3.9)
 No CR to/early relapse after conventional chemotherapy 45 (29.0)
 No CR to/early relapse after allogeneic SCT 5 (3.2)
 No CR to other prior treatment 32 (20.6)
  1. t-AML indicates treatment related AML; AML-RCA, AML with recurrent cytogenetic abnormalities; AML-MRF, AML with MDS related features; MPN, myeloproliferative neoplasia; MLD, multilineage dysplasia; MRC, MDS-related cytogenetics; AML-NOS, AML not otherwise specified; MP, myeloproliferative; COPD, chronic obstructive pulmonary disease; NHL, non-Hodgkin’s lymphoma; ECOG, Eastern Cooperative Oncology Group; CR, complete response; SCT, stem cell transplantation;
  2. *If a patient fulfilled criteria for more than one WHO-category, weighting was performed as follows: t-AML > AML-RCA > AML-MRF.
  3. †BM-blast count was <20%, in those patients with established AML who were refractory to, -or had no CR after-, conventional chemotherapy or allogeneic stem cell transplantation.
  4. ‡Pre-treatment cytogenetics were available in 92% of patients and were determined by conventional metaphase karyotyping (46%), interphase-FISH (16%), or both (38%).
  5. §Numbers may add up to >100% as multiple selections were possible.
  6. #None of the patients for whom azacitidine was intended as bridging was in complete remission to prior therapies, and all patients had relapsed after multiple lines of intensive chemotherapy; only one of these patients proceeded to allogeneic SCT (the others died whilst still on, or within 8 weeks after termination of azacitidine treatment due to disease progression and/or infectious complications).